The Future of TAVR with Wayne Paterson of Anteris Technologies

On this episode of The Medical Alley Podcast, we have a conversation with Wayne Paterson, CEO and Managing Director of Anteris Technologies.

In late December of 2024, Anteris Technologies launched an IPO to support the development of DurAVR, a Transcatheter Heart Valve (THV) designed to treat aortic stenosis. Wayne discusses the IPO and DurAVR’s development, the future of Anteris Technologies, and why the company has chosen Minnesota as the site of its global headquarters.

Send us a message!

Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.